Project title: Intra-arterial Peptide Receptor Radionuclide Therapy (IA-PRRT) using 90Y-DOTA-TOC

Thomas Hope, MD University of California, San Francisco

Thomas Hope, MD
  • Status: Active
  • Year(s): 2016
  • Grant Type: Collaborative
  • Research Type: Clinical
  • Primary Tumor Site: Other
  • Area of Inquiry: Clinical trials
The primary goals are to evaluate possible liver, bone marrow and kidney toxicity after hepatic arterial injection and evaluate imaging tumor response to 90Y-DOTA-TOC hepatic arterial injection three months after treatment. Dr. Hope will evaluate possible 90Y-DOTA-TOC hepatic, marrow and renal toxicity and imaging of tumor response to hepatic arterial injection, three months post-therapy.

Additional Details

  • City: San Francisco
  • State: California
  • Grant Partner: Education and Research Foundation for Nuclear Medicine and Molecular Imaging
  • Sponsor: Margie & Robert E. Petersen Foundation

DISCLAIMER

NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.

« Back to all funded research projects